Keyphrases
Graft-versus-host Disease (GvHD)
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
88%
Overall Survival
59%
Transplantation
44%
Multiple Myeloma
44%
Unrelated Donor
41%
Bone Marrow
41%
Allogeneic Transplantation
38%
Reduced Intensity
37%
Acute Myeloid Leukemia
35%
Reduced-intensity Conditioning
35%
Survivors
31%
Non-relapse Mortality
30%
Marrow Transplantation
29%
Oleate
29%
Hematopoietic Stem Cell Transplantation
28%
Bone Marrow Transplantation
27%
Antithymocyte Globulin
26%
Leukemia
26%
Granulocyte Colony-stimulating Factor (G-CSF)
25%
Fludarabine
25%
Autologous Transplantation
24%
Hematopoietic Cell Transplantation
24%
Engraftment
23%
Myelofibrosis
23%
Non-Hodgkin Lymphoma
23%
Oncology Care
22%
HLA Matching
22%
Methotrexate
22%
Retrospective Analysis
22%
CD34+
22%
Plasma Membrane
21%
Hematopoietic Stem Cell Transplant
21%
Progression-free Survival
20%
Allogeneic Bone Marrow Transplantation
20%
Myelodysplastic Syndrome
19%
Severe Aplastic Anemia
19%
Saturable
19%
Stem Cell Transplantation
19%
Fatty Acid Uptake
19%
Relative Risk
19%
Confidence Interval
19%
Hematological Malignancies
18%
Lymphoma
17%
Allogeneic
17%
Dihydrofolate Reductase Gene
17%
Transgenic Mice
17%
First Complete Remission
16%
Peripheral Blood Progenitor Cells
16%
Risk Factors
15%
Medicine and Dentistry
Transplantation
99%
Hematopoietic Cell
73%
Overall Survival
65%
Cell Transplantation
54%
Allograft
44%
Disease
38%
Multiple Myeloma
37%
Acute Myeloid Leukemia
36%
Graft Versus Host Reaction
35%
Chronic Graft Versus Host Disease
33%
Reduced Intensity Conditioning
33%
Leukemia
31%
Conditioning
26%
Non-Hodgkin Lymphoma
25%
Progression Free Survival
22%
Myelodysplastic Syndrome
22%
Allogeneic Hematopoietic Stem Cell Transplantation
21%
Engraftment
20%
Cord Blood
19%
Oncology
19%
Bone Marrow Transplantation
19%
Hematologic Malignancy
18%
Fludarabine
18%
Autotransplantation
18%
Thymocyte Antibody
18%
Cord Blood Stem Cell Transplantation
18%
Stem Cell Therapy
17%
Myelofibrosis
17%
Graft Failure
17%
Acute Lymphoblastic Leukemia
17%
Allogenic Bone Marrow Transplantation
17%
Prostate Cancer
17%
Oleic Acid
17%
Chemotherapy
14%
Placebo
14%
Lenalidomide
14%
Health Care Cost
14%
Aplastic Anemia
13%
Acute Leukemia
13%
Low Drug Dose
13%
Malignant Neoplasm
13%
Stem Cell Transplant
12%
Progenitor Cell
12%
Fatty Acid
12%
Nonmyeloablative Conditioning
12%
Human Leukocyte Antigen
12%
T Cell
12%
Acute Graft Versus Host Disease
12%
Central Nervous System
11%
Granulocyte Colony Stimulating Factor
11%
Immunology and Microbiology
Graft-Versus-Host Disease
67%
Hematopoietic Cell
59%
Overall Survival
53%
Conditioning
51%
Cell Transplantation
39%
Allograft
37%
Engraftment
31%
Chronic Graft Versus Host Disease
28%
Anti-Thymocyte Globulin
27%
Myeloid
26%
Methotrexate
22%
Multiple Myeloma
20%
Progression Free Survival
18%
Granulocyte Colony-Stimulating Factor
18%
Acute Graft Versus Host Disease
17%
Bone Marrow Transplantation
17%
Transgenic Mouse
17%
Allogeneic Bone Marrow Transplantation
17%
Allogeneic Hematopoietic Stem Cell Transplantation
17%
Fatty Acid Transport
17%
Umbilical Cord Blood
15%
Protein Binding
14%
Stem Cell Transplant
14%
CD34
13%
Cell Membrane
13%
Chimera
13%
Autotransplantation
12%
Cord Blood Stem Cell Transplantation
12%
Human Leukocyte Antigen
12%
Hematopoietic Stem Cell Transplantation
11%
HLA Matching
11%
Autoimmune Hemolytic Anemia
11%
Low Drug Dose
11%
Stem Cell Transplantation
11%
Stem Cell
11%
T Cell Depletion
9%
T Cell
9%
Allele
9%
Hematopoiesis
8%
Fibroblast
8%
Disease Free Survival
8%
Syngenic
8%
Isograft
7%
Platelet
7%
Autologous Stem Cell Transplantation
7%
Host
7%
Drug Megadose
7%
Homeostasis
7%
Immunity
7%
Immunofluorescence
7%